New Delhi: In a major boost up to India's fight against COVID-19, the Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech's Covaxin for children aged between 2-18 years. Covaxin, notably, has become the country's first COVID-19 vaccine that can be administered to children.
This development came after Hyderabad-based Bharat Biotech had completed Phase-II and Phase-III trials of Covaxin in September on children below 18 years of age. The company had submitted the trial data to the DCGI earlier this month.
DCGI said, “After detailed deliberation, the committee recommended for grant of market authorization" to children in age group of 2-18 years. It added that "The emergency use authorisation, however, is subject to certain conditions. The developer of Covaxin will continue the study as per Whole Virion, Inactivated Corona Virus Vaccine the approved clinical trial protocol."
An AIIMS professor has recently claimed that the latest trials show that the safety and immunogenicity of Covaxin are almost the same in kids, as adults above 18 years of age. Dr Sanjay K Rai, a professor at the Centre for Community Medicine, AIIMS